A federal appeals court heard arguments Sept. 9 over whether Louisiana can sue to force a nationwide return to in-person dispensing of the abortion and miscarriage medication mifepristone, and judges on the panel focused heavily on whether the state has the legal right to bring the case at all. The three-judge panel of the 5th U.S. Circuit Court of Appeals in New Orleans issued no ruling and set no timeline for one.
Telehealth prescribing and mail delivery of mifepristone remain available nationwide for now, protected by a Supreme Court stay issued in May that paused an earlier, favorable ruling for Louisiana while this appeal proceeds.
Background
Louisiana sued the FDA in October 2025 over the agency’s 2023 decision eliminating the requirement that mifepristone be dispensed in person, a change that allowed certified prescribers to issue it through telehealth and pharmacies to mail it to patients. Louisiana argues the FDA acted without adequate safety review and that the rule undermines its own near-total abortion ban, since the medication still reaches Louisiana residents by mail from out-of-state providers. The state has separately indicted out-of-state doctors for prescribing mifepristone to its residents and challenged shield laws in states like California and New York that protect providers from such prosecutions.
Despite Louisiana’s ban, the state saw more abortions in 2025 than it did before Roe v. Wade was overturned in 2022, with more than 10,000 residents obtaining abortion medication through telehealth prescriptions mailed into the state, according to data from the Society of Family Planning. The FDA is separately conducting its own safety review of mifepristone, promised to Republican state attorneys general last year and expected to take six months; that review had not concluded as of the September hearing.
What Different Sides Are Saying
Louisiana, represented by Alliance Defending Freedom, argues mifepristone carries risks including heavy bleeding and rare life-threatening infection, and that the FDA should not have removed the in-person dispensing requirement without a fuller safety review. Fact-check: more than 100 peer-reviewed studies and data from more than 7.5 million uses since the drug’s 2000 approval are commonly cited by medical organizations, including the American College of Obstetricians and Gynecologists, as supporting its safety, including when prescribed by telehealth; this reflects the mainstream position among major medical associations, though it does not resolve the separate legal question of whether the FDA’s specific 2023 process was adequate.
The FDA, defending its own 2023 rule in court, argues the change was supported by the medical evidence available and that Louisiana’s claimed injuries, including Medicaid costs from treating complications, are too indirect to give the state standing to sue, since they depend on the independent choices of patients and providers in other states. Fact-check: multiple outlets covering the hearing described the panel’s questions as skeptical of Louisiana’s standing on similar grounds, though skepticism at oral argument does not guarantee a particular outcome, and the panel issued no ruling.
The current administration occupies an unusual position in this case: its own FDA is defending the Biden-era 2023 telehealth rule in court, while separately conducting a fresh safety review of the same medication that it promised to anti-abortion state officials. This article treats that as a documented tension in the administration’s overall posture rather than a contradiction requiring resolution, since the litigation and the review are separate processes on separate timelines.
Note on Scope
This is one of three similar cases moving through federal courts seeking to restrict cross-state telehealth access to abortion medication. This article covers the Louisiana case specifically and does not report on the other two.
Related Links
- Louisiana v. FDA: Abortion Pill Access Under Fire – Center for Reproductive Rights
- Federal Appeals Court Hears Challenge to the Abortion Pill Mifepristone, Again – ACLU
- State asks appeals court to block telehealth access to abortion medications – Verite News
- Fifth Circuit Judges Seem Skeptical of Louisiana’s Challenge to Telehealth Abortion – Ms. Magazine
- Fifth Circuit Judges Press Louisiana on Standing as Mifepristone Stays Available by Mail – Medical Daily
- Fifth Circuit Questions Louisiana’s Standing in Mifepristone Case – The Epoch Times
Discussion Questions
- Should a state be able to sue over a federal rule affecting a drug mailed in from other states?
- Do you find Louisiana’s safety concerns or the FDA’s standing argument more persuasive?
- Why do you think Louisiana is seeing more abortions since its ban took effect, not fewer?
- How should courts weigh state-level enforcement interests against federal drug regulation authority?
- What responsibility does the FDA have to complete its own safety review before this case is decided?
- Should shield laws protecting out-of-state medical providers hold up against another state’s prosecution efforts?
- How should the public interpret judges’ skeptical questions at oral argument, short of an actual ruling?
- What would change for you personally if telehealth abortion pill access were restricted nationwide?
- Do you think the administration’s dual posture here, defending one rule while reviewing the same drug, is a meaningful tension or business as usual?
- Imagine you are one of the appellate judges. What single piece of evidence would most affect your view of Louisiana’s standing?
